Title: A Phase II Pilot Trial Of Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and the Addition Of Paricalcitol Upon Disease Progression in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Disease site: Pancreatic cancer
Status: In follow up (closed to recruitment)

Trial Design: Open label, phase II trial that aims to evaluate the efficacy and safety of adding paricalcitol to paclitaxel protein bound cisplatin, and gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma. Participants will initially receive paclitaxel protein bound cisplatin and gemcitabine until disease progression at which point paricalcitol will be introduced to the chemotherapy regimen until further disease progression. Following that patients will enter a follow up phase for disease and survival status. Participants will undergo tumour biopsies before prior to and on paricalcitol plus chemotherapy treatment. PINBALL is associated with an extensive translational program.

Trial details

Chief Investigator: Dr Sarah Slater
Trial contact:
Clinical -
EudraCT: 2017-004467-13
Sponsor: Barts Health NHS Trust
Participating countries: UK
Source of funding: Stand Up To Cancer/CRUK/Lustgarten Foundation (Ref: SU2C-AACR-D7-20-16)

Clinical Trial Portfolio

Click here to to see a list of our clinical trials that are currently in set up or those that are open to recruitment.